Safety Pal-GHK has been tested in clinical studies where it was found to be safe, with no adverse events being reported [9]
Incretin-like drugs mimic these hormones, and while we do not have any head-to-head trials, you can see from the informative Figure below, summarizing best results of this family of drugs to date, moving from single agonist GLP-1 to double and then triple (GLP-1-GIP-GCG), there is incremental body weight loss
Typical research protocols: 5-10mg for pilot studies, 20-50mg for standard investigations, 100mg+ for large-scale or longitudinal studies
In the Phase 3 TRIUMPH-1 trial, the 12 mg group showed an average weight loss of 28.3% over 80 weeks
You have one scoop of powder
A person should not use conversion estimates to change doses on their own